UNICYCIVE THERAPEUTICS, INC. Noninterest Expense Investment Advisory Fees
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Noninterest Expense Investment Advisory Fees of $100.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:NoninterestExpenseInvestmentAdvisoryFees · last filed 2023-03-31
- UNICYCIVE THERAPEUTICS, INC. noninterest expense investment advisory fees for fiscal 2022 was $100.00K.
| Period end | Noninterest Expense Investment Advisory Fees | Noninterest Expense Investment Advisory Fees 12 month |
|---|---|---|
| 2022-12-31 | $100.00K 10-K · filed 2023-03-31 | |
| 2021-07-31 | $150.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |